Antibody-based Therapies in Multiple Myeloma

Overview

Journal Bone Marrow Res

Date 2011 Nov 3

PMID 22046572

Citations 28

Authors

Yu-Tzu Tai

Kenneth C Anderson

Affiliations

Soon will be listed here.

Abstract

The unmet need for improved multiple myeloma (MM) therapy has stimulated clinical development of monoclonal antibodies (mAbs) targeting either MM cells or cells of the bone marrow (BM) microenvironment. In contrast to small-molecule inhibitors, therapeutic mAbs present the potential to specifically target tumor cells and directly induce an immune response to lyse tumor cells. Unique immune-effector mechanisms are only triggered by therapeutic mAbs but not by small molecule targeting agents. Although therapeutic murine mAbs or chimeric mAbs can cause immunogenicity, the advancement of genetic recombination for humanizing rodent mAbs has allowed large-scale production and designation of mAbs with better affinities, efficient selection, decreasing immunogenicity, and improved effector functions. These advancements of antibody engineering technologies have largely overcome the critical obstacle of antibody immunogenicity and enabled the development and subsequent Food and Drug Administration (FDA) approval of therapeutic Abs for cancer and other diseases.

Citing Articles

Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma.

Luca F, Allegra A, Di Chio C, Previti S, Zappala M, Ettari R Int J Mol Sci. 2023; 24(4).

PMID: 36834545 PMC: 9959320. DOI: 10.3390/ijms24043136.

Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.

Offidani M, Corvatta L, More S, Olivieri A Drug Des Devel Ther. 2021; 15:2401-2415.

PMID: 34103900 PMC: 8180291. DOI: 10.2147/DDDT.S267404.

Boosting Immunity against Multiple Myeloma.

Lopes R, Ferreira B, Caetano J, Barahona F, Carneiro E, Joao C Cancers (Basel). 2021; 13(6).

PMID: 33799565 PMC: 8001641. DOI: 10.3390/cancers13061221.

Immunotherapeutic and Targeted Approaches in Multiple Myeloma.

Nadeem O, Tai Y, Anderson K Immunotargets Ther. 2020; 9:201-215.

PMID: 33117743 PMC: 7569026. DOI: 10.2147/ITT.S240886.

Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma.

Biteghe F, Chalomie N, Mungra N, Vignaux G, Gao N, Vergeade A Biomedicines. 2020; 8(9).

PMID: 32899183 PMC: 7555584. DOI: 10.3390/biomedicines8090327.

References

Sainz I, Isordia-Salas I, Espinola R, Long W, Pixley R, Colman R . Multiple myeloma in a murine syngeneic model:modulation of growth and angiogenesis by a monoclonal antibody to kininogen. Cancer Immunol Immunother. 2005; 55(7):797-807. PMC: 11030674. DOI: 10.1007/s00262-005-0068-8. View

Berkova Z, Tao R, Samaniego F . Milatuzumab - a promising new immunotherapeutic agent. Expert Opin Investig Drugs. 2009; 19(1):141-9. DOI: 10.1517/13543780903463854. View

Tai Y, Li X, Breitkreutz I, Song W, Neri P, Catley L . Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006; 66(13):6675-82. DOI: 10.1158/0008-5472.CAN-06-0190. View

Novak A, Darce J, Arendt B, Harder B, Henderson K, Kindsvogel W . Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2003; 103(2):689-94. DOI: 10.1182/blood-2003-06-2043. View

Moreau P, Harousseau J, Wijdenes J, Morineau N, Milpied N, Bataille R . A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol. 2000; 109(3):661-4. DOI: 10.1046/j.1365-2141.2000.02093.x. View

Tai Y, Li X, Tong X, Santos D, Otsuki T, Catley L . Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005; 65(13):5898-906. DOI: 10.1158/0008-5472.CAN-04-4125. View

Burkiewicz J, Scarpace S, Bruce S . Denosumab in osteoporosis and oncology. Ann Pharmacother. 2009; 43(9):1445-55. DOI: 10.1345/aph.1M102. View

Darce J, Arendt B, Wu X, Jelinek D . Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol. 2007; 179(11):7276-86. DOI: 10.4049/jimmunol.179.11.7276. View

Gorski D, Beckett M, Jaskowiak N, Calvin D, Mauceri H, Salloum R . Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999; 59(14):3374-8. View

10.

Ozaki S, Kosaka M, Wakahara Y, Ozaki Y, Tsuchiya M, Koishihara Y . Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells. Blood. 1999; 93(11):3922-30. View

11.

Ozaki S, Kosaka M, Wakatsuki S, Abe M, Koishihara Y, Matsumoto T . Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood. 1997; 90(8):3179-86. View

12.

Podar K, Anderson K . Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies. Cell Cycle. 2007; 6(5):538-42. DOI: 10.4161/cc.6.5.3922. View

13.

Zand M, Vo T, Pellegrin T, Felgar R, Liesveld J, Ifthikharuddin J . Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood. 2005; 107(7):2895-903. PMC: 1895388. DOI: 10.1182/blood-2005-06-2269. View

14.

Romagne F, Andre P, Spee P, Zahn S, Anfossi N, Gauthier L . Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009; 114(13):2667-77. PMC: 2756126. DOI: 10.1182/blood-2009-02-206532. View

15.

Ruckle J, Jacobs M, Kramer W, Pearsall A, Kumar R, Underwood K . Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res. 2008; 24(4):744-52. DOI: 10.1359/jbmr.081208. View

16.

Plushner S . Tocilizumab: an interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother. 2008; 42(11):1660-8. DOI: 10.1345/aph.1L268. View

17.

Hideshima T, Mitsiades C, Tonon G, Richardson P, Anderson K . Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007; 7(8):585-98. DOI: 10.1038/nrc2189. View

18.

Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy Jr J . Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2006; 109(5):2106-11. PMC: 1801040. DOI: 10.1182/blood-2006-09-047712. View

19.

Trikha M, Corringham R, Klein B, Rossi J . Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003; 9(13):4653-65. PMC: 2929399. View

20.

Ryan M, Hering M, Peckham D, McDonagh C, Brown L, Kim K . Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol Cancer Ther. 2007; 6(11):3009-18. DOI: 10.1158/1535-7163.MCT-07-0464. View